Myristoleic acid, a cytotoxic component in the extract from Serenoa repens, induces apoptosis and necrosis in human prostatic LNCaP cells.

BACKGROUND: Prostatic tumors are well known to progress to hormonal therapy-resistant terminal states. At this stage, there are no chemotherapeutic agents to affect clinical outcome. An effective cell death inducer for these prostate cells may be a candidate as an attractive antitumor agent. The extracts from S. repens have been used to improve the state of prostatic diseases and we have attempted to identify the effective component from the extract. METHODS: Cell viability was examined in LNCaP cells, an in vitro model for hormonal therapy-resistant prostatic tumor. RESULTS: We found that exposure of the extract from S. repens resulted in cell death of LNCaP cells. We also identified myristoleic acid as one of the cytotoxic components in the extract. The cell death exhibited both apoptotic and necrotic nuclear morphology as determined by Hoechst 33342 staining. Cell death was also partially associated with caspase activation. CONCLUSIONS: It was demonstrated that the extract from S. repens and myristoleic acid induces mixed cell death of apoptosis and necrosis in LNCaP cells. These results suggest that the extract and myristoleic acid may develop attractive new tools for the treatment of prostate cancer.

[Japanese cedar pollinosis in infants in the allergy clinic].

Recently, the number of patients with Japanese cedar (Cryptomeria japonica) pollinosis has increased, especially in children. However, little is known about the incidence in infants. We studied on the rate of sensitization and the onset of pollinosis in children under 6 years old. The percentage of positive CAP-RAST to Japanese cedar pollen was 27.6%, in 76 infants (51 male and 25 female, 2 months-5 years old) who visited National Mie Hospital pediatric allergy clinic due to bronchial asthma and/or atopic dermatitis. The youngest child who has been sensitized to pollen was 1 year 8 month old boy. The percentage of positive rate of CAP-RAST to house dust mite was 61.8%. Twenty-seven infants (20 male and 7 female, 2-5 years of age) were diagnosed as Japanese cedar pollinosis in National Mie Hospital Otorhinolaryngology clinic in 1999 and 2000. The youngest child with pollinosis was 2 year 5 month old boy. Most of the 27 infants complained of rhinorrhea and/or eye symptoms and some of them complained cough, snoring, or epistaxis. About 40% were sensitized to Japanese cedar and/or cupressaceae pollen alone, 60% were also sensitized to house dust mite. In conclusion, it is possible that the sensitization to Japanese cedar pollen occurs after 2 season of pollen exposure and pollinosis occurs in 2 years old. Japanese cedar pollen has been an important allergen not only in school children, but also in infants.

Gonadotropin-releasing hormone-associated peptide immunoreactivity in bovine colostrum.

Gonadotropin-releasing hormone(GnRH)-associated peptide (GAP) is a 56-amino acid peptide found on the C-terminal of the GnRH (also called luteinizing hormone-releasing hormone) precursor and is assumed to be co-produced with GnRH. The purpose of this report is to demonstrate the presence of GAP immunoreactivity in bovine colostrum. Radioimmunoassay of acidified methanolic extracts demonstrated a concentration of GAP immunoreactivity of approximately 1.5 +/- 0.1 pmol/g dry skim bovine colostrum. Gel filtration (Sephadex G-10) and high-performance liquid chromatography of extracts containing GAP immunoreactivity showed it to be of low molecular weight and a high hydrophobic character. The presence of GAP immunoreactivity in bovine colostrum suggests that the GnRH precursor is synthesized and processed in mammary tissue itself.

[Adjuvant chemotherapy for gastric cancer--relation between long-term administration of FT-207 and prognosis].

The effect of adjuvant chemotherapy with FT-207 on survival rates in gastric cancer patients was evaluated. Patients who underwent curative gastrectomy in our Department were classified into the four groups: (A) short-term chemotherapy; total doses of 5 g 5-fluorouracil, or 1/2 MF (F') C alone (futraful 400mg/day, or 5-fluorouracil 250 mg/day for 3 weeks, mitomycin C 2 mg and cytosine arabinoside 20 mg twice a week for 3 weeks; (B) intermediate term chemotherapy; 1/2 MF (F') C followed by the oral administration of futraful 0.6g/day for less than 6 months; (C) long-term chemotherapy; 1/2 MF (F') C followed by futraful 10.6g/day longer than 6 months (D) control; no chemotherapy No significant difference back ground factors among four groups was found. Patients who recurred during the administration of drugs were excluded from this study. The survival rate of Group (C) in stage III was significantly higher than that of Group (A), (B) and (D) (generalized Wilcoxon test, p less than 0.03). There was no difference between (B) and (D). The survival rate of Group (A) was lower than Group (D). The effectiveness of chemo- therapy was not observed in patients with stage I and II. Survival rates of patients receiving futraful longer than 3 months continuously were significantly higher compared to patients who had to discontinue the drugs due to side effects. These results suggested that the adjuvant chemotherapy with futraful lasting more than 6 months prolonged the survival time, but short-term chemotherapy decreased the survival rate when compared with no chemotherapy group.

[Chemotherapy of gastric cancer patients with hepatic metastases].

The effect of post-operative adjuvant chemotherapy on the prognosis of gastric cancer patients with hepatic metastases was evaluated. Forty-two cases were classified into-following four groups: (A) no chemotherapy, (B) short-term chemotherapy (5 g of 5 FU i.v., or 1/2 FM (F') C alone), (C) long-term chemotherapy (1/2 MF (F') C plus 0.6 g of FT-207 per os), (D) long-term chemotherapy (1/2 MF (F') C plus 1.5 g/day of FT-207 per annum). Six, nine, twelve month survival rates of patients in group (D) was significantly higher than group (A). Mean survival time of each group was: (A) 4.7, (B) 5.2, (C) 5.7 and (D) 9.1 months. Correlation between the survival time and the total dose of FT-207 was observed. Total dose of FT-207 in group (D) was 129.3 g and 60.8 g in group (C). These may reflect the results that the rectal administration was more effective than the oral administration of FT-207.